These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

603 related items for PubMed ID: 29374157

  • 1. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
    Wang L, Dong X, Ren Y, Luo J, Liu P, Su D, Yang X.
    Cell Death Dis; 2018 Jan 26; 9(2):129. PubMed ID: 29374157
    [Abstract] [Full Text] [Related]

  • 2. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
    Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.
    Mol Cancer Ther; 2012 Jan 26; 11(1):204-13. PubMed ID: 22075159
    [Abstract] [Full Text] [Related]

  • 3. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G.
    Lung Cancer; 2014 Feb 26; 83(2):146-53. PubMed ID: 24331411
    [Abstract] [Full Text] [Related]

  • 4. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.
    Zhongguo Fei Ai Za Zhi; 2012 Dec 26; 15(12):689-93. PubMed ID: 23249714
    [Abstract] [Full Text] [Related]

  • 5. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
    Xu X, Liu Y, Gong Q, Ma L, Wei W, Zhao L, Luo Z.
    Cancer Chemother Pharmacol; 2024 Aug 26; 94(2):209-221. PubMed ID: 38609654
    [Abstract] [Full Text] [Related]

  • 6. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
    Huang J, Lan X, Wang T, Lu H, Cao M, Yan S, Cui Y, Jia D, Cai L, Xing Y.
    Oncogene; 2020 Feb 26; 39(8):1739-1755. PubMed ID: 31740781
    [Abstract] [Full Text] [Related]

  • 7. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 26; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 8. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 9. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Dec 02; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 02; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 11. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
    To KKW, Wu WKK, Loong HHF.
    Eur J Pharmacol; 2018 Mar 15; 823():19-26. PubMed ID: 29378193
    [Abstract] [Full Text] [Related]

  • 12. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.
    Ali A, Levantini E, Teo JT, Goggi J, Clohessy JG, Wu CS, Chen L, Yang H, Krishnan I, Kocher O, Zhang J, Soo RA, Bhakoo K, Chin TM, Tenen DG.
    EMBO Mol Med; 2018 Mar 15; 10(3):. PubMed ID: 29449326
    [Abstract] [Full Text] [Related]

  • 13. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 Mar 15; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 14. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
    Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK.
    Clin Cancer Res; 2018 Dec 15; 24(24):6523-6535. PubMed ID: 30194074
    [Abstract] [Full Text] [Related]

  • 15. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 15; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 16. Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
    Bidkhori G, Moeini A, Masoudi-Nejad A.
    PLoS One; 2012 Aug 15; 7(10):e48004. PubMed ID: 23133538
    [Abstract] [Full Text] [Related]

  • 17. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
    Ni J, Zhou LL, Ding L, Zhao X, Cao H, Fan F, Li H, Lou R, Du Y, Dong S, Liu S, Wang Z, Ma R, Wu J, Feng J.
    Exp Cell Res; 2017 Dec 15; 361(2):246-256. PubMed ID: 29080795
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
    Chen J, Cui JD, Guo XT, Cao X, Li Q.
    Cancer Med; 2018 Apr 15; 7(4):1394-1403. PubMed ID: 29493886
    [Abstract] [Full Text] [Related]

  • 20. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
    Yang C, Ma S, Zhang J, Han Y, Wan L, Zhou W, Dong X, Yang W, Chen Y, Gao L, Cui W, Jia L, Yang J, Wu C, Wang Q, Wang L.
    Proc Natl Acad Sci U S A; 2024 Jun 04; 121(23):e2317790121. PubMed ID: 38814866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.